Why the study?
Do sirolimus- or paclitaxel-eluting stents improve 2-year clinical outcomes compared to bare metal stents in patients with diabetes mellitus?
Population
708 consecutive diabetic patients (25% insulin treated) from the RESEARCH and T-SEARCH registries
Comparison
Sirolimus-eluting stents or paclitaxel-eluting… vs Bare metal stents (BMS, n=252)
Design
Cohort
Follow-up
2 years
Authors
Loading...
Adjusted analyses show no MACE benefit of DES over BMS in diabetes; leaves open need for randomized confirmation before practice change.
Do sirolimus- or paclitaxel-eluting stents improve 2-year clinical outcomes compared to bare metal stents in patients with diabetes mellitus?
In a real-world registry of diabetic patients, drug-eluting stents (SES and PES) did not demonstrate a statistically significant long-term clinical benefit over bare metal stents after propensity adjustment.
Daemen et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: